BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2024 8:28:55 AM | Browse: 202 | Download: 1056
Publication Name World Journal of Clinical Oncology
Manuscript ID 93717
Country Portugal
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Successful cetuximab rechallenge in metastatic colorectal cancer: A case report
Manuscript Source Unsolicited Manuscript
All Author List Alexandra Guedes, Sandra Silva, Sandra Custódio and Andreia Capela
ORCID
Author(s) ORCID Number
Alexandra Guedes http://orcid.org/0009-0005-1637-5207
Funding Agency and Grant Number
Corresponding Author Alexandra Guedes, MD, Doctor, Doctor, Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Rua Conceição Fernandes S/N, Vila Nova de Gaia 4434-502, Portugal. alexandra.pereira.guedes@ulsge.min-saude.pt
Key Words Metastatic colorectal cancer; RAS mutation; RAS wild type; Anti-epidermal growth factor receptor; Cetuximab; Rechallenge; Case report
Core Tip In RAS-wild type patients treated with anti-epidermal growth factor receptor-inhibitors, the emergence of RAS mutations leads to resistance to further anti-epidermal growth factor receptor treatment. However, resistant clones seem to decay over time upon treatment withdrawal. Liquid biopsy-driven cetuximab rechallenge can be effective in later lines of treatment of metastatic colorectal cancer. Longer anti-epidermal growth factor receptor-free intervals may act as a surrogate for improved responses and survival outcomes.
Publish Date 2024-08-29 08:28
Citation

Guedes A, Silva S, Custódio S, Capela A. Successful cetuximab rechallenge in metastatic colorectal cancer: A case report. World J Clin Oncol 2024; 15(9): 1232-1238

URL https://www.wjgnet.com/2218-4333/full/v15/i9/1232.htm
DOI https://dx.doi.org/10.5306/wjco.v15.i9.1232
Full Article (PDF) WJCO-15-1232-with-cover.pdf